| Literature DB >> 35829808 |
Jialiang Yang1, Yuhong Chen2, Tongdan Zou1, Bai Xue1, Fang Yang1, Xiangzhou Wang3, Yibo Huo3, Boyun Yan3, Yuxia Xu1, Shiyu He1, Yi Yin4, Jing Wang4, Xiong Zhu1, Lin Zhang1, Yu Zhou1, Zhengfu Tai1, Ping Shuai1, Man Yu5, Qian Luo5, Yilian Cheng5, Bo Gong1,6, Xianjun Zhu1,6, Jing Zhang3, Xinghuai Sun2, Ying Lin1, Houbin Zhang7, Zhenglin Yang8,9,10.
Abstract
Genome-wide association studies have suggested a link between primary open-angle glaucoma and the function of ABCA1. ABCA1 is a key regulator of cholesterol efflux and the biogenesis of high-density lipoprotein (HDL) particles. Here, we showed that the POAG risk allele near ABCA1 attenuated ABCA1 expression in cultured cells. Consistently, POAG patients exhibited lower ABCA1 expression, reduced HDL, and higher cholesterol in white blood cells. Ablation of Abca1 in mice failed to form HDL, leading to elevated cholesterol levels in the retina. Counting retinal ganglion cells (RGCs) by using an artificial intelligence (AI) program revealed that Abca1-deficient mice progressively lost RGCs with age. Single-cell RNA sequencing (scRNA-seq) revealed aberrant oxidative phosphorylation in the Abca1-/- retina, as well as activation of the mTORC1 signaling pathway and suppression of autophagy. Treatment of Abca1-/- mice using atorvastatin reduced the cholesterol level in the retina, thereby improving metabolism and protecting RGCs from death. Collectively, we show that lower ABCA1 expression and lower HDL are risk factors for POAG. Accumulated cholesterol in the Abca1-/- retina causes profound aberrant metabolism, leading to a POAG-like phenotype that can be prevented by atorvastatin. Our findings establish statin use as a preventive treatment for POAG associated with lower ABCA1 expression.Entities:
Keywords: ABCA1; HDL; atorvastatin; cholesterol; glaucoma; retinal ganglion cell
Year: 2022 PMID: 35829808 DOI: 10.1007/s11427-021-2126-2
Source DB: PubMed Journal: Sci China Life Sci ISSN: 1674-7305 Impact factor: 10.372